Acute Myeloid Leukemia
Conditions
Interventions
Treatment group for refractory/relapsed AML using novel HDS technology:Treatment guided by effective drug predictions based on the novel HDS detection technology system.
Treatment Based on Prior Medication and 2023 NCCN AML Guidelines:Treatment Based on Prior Medication and 2023 NCCN AML Guidelines
Sponsors
The Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1: Patients with refractory or relapsed AML 2: No gender restriction; age 18–70 years; Karnofsky Performance Status (KPS) score >60; estimated survival >3 months 3: No severe impairment of major organ functions: Creatinine 55% Hemoglobin >90 g/L, bilirubin <2.0 mg/dL 4: No uncontrolled severe infections or severe graft-versus-host disease (GVHD) 5: Voluntary participation with signed informed consent
Exclusion criteria
Exclusion criteria: 1: Severe cardiac, renal, or hepatic dysfunction. 2: Concurrent malignancy requiring treatment. 3: Clinical symptoms of brain dysfunction or severe psychiatric disorders preventing understanding or compliance with the study protocol. 4: Inability to adhere to follow-up schedules. 5: Inability to complete required treatment plans and follow-up observations. 6: History of severe acute allergic reactions. 7: Participation in other clinical trials. 8: Other conditions deemed unsuitable for clinical trials by investigators.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| effectivity;security;Overall Survival(OS);Leukemia-Free Survival(LFS); | — |
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate(ORR); | — |
Countries
China
Contacts
Public ContactLei Gao
The Second Affiliated Hospital of Army Medical University
Outcome results
None listed